Table 3.

Association of TLR7 rs3853839 with clinical outcome in three cohorts

Genotype	n	RR		PFS					OS
		(%)	P-value	univariate (a)			multivariate (b)		univariate (a)			multivariate (b)
				median month(95% CI)	HR (95% CI)	P-value		P-value	median month(95% CI)	HR (95% CI)	P-value		P-value
Discovery cohort
G/G	37	81%	0.16	11.8 (8.8, 15.0)	1 (Reference)	0.073	1 (Reference)	0.37	36.4 (29.8, 70.8)	1 (Reference)	0.042	1 (Reference)	0.19
G/C	20	56%		6.3 (3.9, 12.2)	1.90 (1.08, 3.35)		1.33 (0.71, 2.50)		16.0 (9.5, 45.0)	2.43 (1.20–4.92)		1.96 (0.90, 4.26)
C/C	172	72%		10.3 (9.0, 12.2)	1.33 (0.90, 1.97)		1.32 (0.89, 1.96)		28.7 (23.8, 37.5)	1.47 (0.87, 2.50)		1.52 (0.89, 2.61)
G/G	37	81%	0.30	11.8 (8.8, 15.0)	1 (Reference)	0.092	1 (Reference)	0.16	36.4 (29.8, 70.8)	1 (Reference)	0.095	1 (Reference)	0.10
Any C	192	70%		10.0 (8.7, 11.1)	1.38 (0.94, 2.04)		1.32 (0.90, 1.96)		27.6 (22.6, 37.1)	1.05 (0.70, 1.58)		1.56 (0.92, 2.66)
Validation cohort
G/G	39	81%	0.39	11.6 (9.4, 16.3)	1 (Reference)	0.006	1 (Reference)	0.015	36.2 (26.5, 42.8)	1 (Reference)	0.53	1 (Reference)	0.52
Any C	31	70%		9.1 (5.6, 13.8)	2.04 (1.18, 3.55)		2.02 (1.14, 3.55)		30.5 (19.0, 38.3)	1.25 (0.60, 2.60)		1.27 (0.61, 2.68)
Control cohort
G/G	30	67%	0.83	11.1 (8.8, 13.5)	1 (Reference)	0.69	1 (Reference)	0.53	30.3 (26.1, 40.0)	1 (Reference)	0.15	1 (Reference)	0.24
Any C	200	62%		10.2 (9.2, 11.7)	0.92 (0.61, 1.39)		0.88 (0.58, 1.33)		23.6 (20.6, 25.9)	1.45 (0.87, 2.38)		1.35 (0.81, 2.27)

P value was based on Fisher’s exact test for tumor response, log-rank test for PFS and OS in the univariate analysis (a) and Wald test for PFS and OS in the multivariate Cox regression model adjusted for sex, ECOG performance status, liver limited metastasis, primary tumor resection in the training and control cohort; adjusted for tumor site, number of metastases, lymph nodes involvement in the validation cohort (b). Correlations with p<0.1 are marked with bold text style.